Table 1.
Clinicopathological characteristics
| Variable | n = 166 | SARIFA-positive (n = 53) | SARIFA-negative (n = 113) | p-value | |||
|---|---|---|---|---|---|---|---|
| Median age (range), years | 68.0 (44–85) | 67.5 (45–83) | 65.8 (44–85) | 0.285 | |||
| Sex | 0.388 | ||||||
| Female | 77 | 46% | 22 | 41% | 55 | 49% | |
| Male | 89 | 54% | 31 | 59% | 58 | 51% | |
| pT status | 0.674 | ||||||
| pT1 | 21 | 13% | 8 | 15% | 13 | 11% | |
| pT2 | 108 | 65% | 35 | 66% | 73 | 65% | |
| pT3 | 37 | 22% | 10 | 19% | 27 | 24% | |
| pN status | 0.782 | ||||||
| Negative | 43 | 26% | 13 | 24% | 30 | 26% | |
| Positive | 123 | 74% | 40 | 76% | 83 | 74% | |
| cM | 0.911 | ||||||
| No | 71 | 43% | 23 | 43% | 48 | 42% | |
| Yes | 95 | 57% | 30 | 57% | 65 | 58% | |
| Histological Grading | 0.155 | ||||||
| G1 | 12 | 7% | 2 | 4% | 10 | 9% | |
| G2 | 106 | 64% | 31 | 58% | 75 | 66% | |
| G3 | 48 | 29% | 20 | 38% | 28 | 25% | |
| Vascular invasion | 0.029 | ||||||
| Negative | 135 | 81% | 38 | 72% | 97 | 86% | |
| Positive | 31 | 19% | 15 | 28% | 16 | 14% | |
| Lymphovascular invasion | 0.455 | ||||||
| Negative | 110 | 66% | 33 | 62% | 77 | 68% | |
| Positive | 56 | 34% | 20 | 38% | 36 | 32% | |
| Perineural invasion | 0.207 | ||||||
| Negative | 24 | 15% | 5 | 9% | 19 | 17% | |
| Positive | 142 | 85% | 48 | 91% | 94 | 83% | |
| R status | 0.734 | ||||||
| R0 | 72 | 43% | 24 | 45% | 48 | 43% | |
| R1 | 94 | 57% | 29 | 55% | 65 | 57% | |
| Local recurrence (n = 85) | 0.526 | ||||||
| Negative | 5 | 6% | 1 | 4% | 4 | 7% | |
| Positive | 80 | 94% | 27 | 96% | 53 | 93% | |
| aCTx (n = 144) | 0.009 | ||||||
| No | 32 | 22% | 16 | 36% | 16 | 16% | |
| Yes | 112 | 78% | 29 | 64% | 83 | 84% | |
CI Confidence interval, pT Pathological assessment of extension of primary tumour (according to the 8th UICC staging system), pN Pathological assessment of lymph node metastasis (according to the 8 th UICC staging system), cM Clinical assessment of distant metastases, R Residual tumour, aCTx Adjuvant (in all schemes)
P values are shown for differences between SARIFA-positive and SARIFA-negative tumours; bold marked values are statistically significant with p < 0.05. Regarding local recurrence (n = 85) and adjuvant chemotherapy (n = 144), data were only available for a subgroup of patients. For all other parameters, the whole cohort (n = 166) was considered.